Francesse Bataille, MD
Internal Medicine · Dumfries, VANPI 1255371613
Payments from drug & device makers
What this record shows
This record is dominated by other: $108,000 of the $108,780 with a category attached, or 99.3%. Convatec Inc. accounts for 99.3% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $108,065, more than ten times the $300 reported in 2019. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $2789.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Convatec Inc.$108K
- AstraZeneca$186
- Amgen$143
- Pfizer$112
- Coala Life Inc$75
- Medtronic$75
- plus $190 from 8 others
What the payments were for
- Food & beverage$6581%
- Education$1220%
- Other$108,00099%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Convatec Inc. | 2 | $108,000 |
| AstraZeneca | 12 | $186 |
| Amgen | 7 | $143 |
| Pfizer | 2 | $112 |
| Coala Life Inc | 4 | $75 |
| Medtronic | 1 | $75 |
| AbbVie(2 entities) | 3 | $49 |
| Novartis | 2 | $34 |
| Lilly USA, LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InnovaMatrix AC$108,000
- EUCRISA$105
How this compares
$108,780 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $66,743 |
| EliquisApixaban | 71 | $54,088 |
| JanuviaSitagliptin Phosphate | 38 | $35,743 |
| JardianceEmpagliflozin | 18 | $26,384 |
| FarxigaDapagliflozin Propanediol | 16 | $25,166 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $14,573 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $11,721 |
| LinzessLinaclotide | 14 | $8,511 |
| MyrbetriqMirabegron | 15 | $8,171 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 29 | $7,489 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 16 | $7,002 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $5,921 |
| Atorvastatin Calcium | 226 | $2,630 |
| Colchicine | 33 | $2,320 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $1,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $12 | $66,74359 claims |
| PfizerEliquis | $112 | $54,08871 claims |
| AstraZenecaFarxiga | $186 | $25,16616 claims |
| AbbVieLinzess | $49 | $8,51114 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $8,17115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Dumfries
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Brian WassermanNorth Chesterfield$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.